Corvus Pharmaceuticals (CRVS) Liabilities and Shareholders Equity (2015 - 2026)

Corvus Pharmaceuticals' Liabilities and Shareholders Equity history runs 12 years deep, the most recent figure standing at $253.2 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 325.98% year-over-year to $253.2 million; the TTM figure through Mar 2026 stood at $494.2 million (up 96.35% YoY), while the FY2025 annual figure was $71.1 million, up 3.21% from the prior year.
• Liabilities and Shareholders Equity was $253.2 million for Q1 2026 at Corvus Pharmaceuticals, up from $71.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $253.2 million in Q1 2026 to a low of $40.1 million in Q1 2024.
• Historically, Liabilities and Shareholders Equity has averaged $79.0 million across 5 years, with a median of $68.2 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Liabilities and Shareholders Equity tumbled 42.54% in 2023, then jumped 325.98% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $68.2 million in 2022, then plunged by 33.25% to $45.6 million in 2023, then surged by 51.27% to $68.9 million in 2024, then grew by 3.21% to $71.1 million in 2025, then jumped by 256.02% to $253.2 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $253.2 million (Q1 2026), $71.1 million (Q4 2025), and $80.5 million (Q3 2025), per Business Quant data.